All products on this site are research reagents for laboratory use only. They are not medicines, not approved for human use, and do not replace medical consultation.
Notice · content is for research purposes. The peptides described are not approved for human consumption and do not constitute medical advice.
As a researcher in the field of molecular biochemistry and receptor pharmacology, my laboratory practice often involves tracking the evolution of synthetic peptide analogues and their transition from basic science to clinical trials. One of the most intensely studied molecules in neuroendocrinology over the past two decades is PT-141, known in the medical literature as bremelanotide. The purpose of this article is to provide objective, evidence-based PT-141 information by reviewing published data on the peptide's interaction with the central nervous system, its mechanism of action, and its current status in scientific research.
PT-141, or bremelanotide, is a synthetic cyclic heptapeptide that structurally represents an analogue of the endogenous alpha-melanocyte-stimulating hormone (α-MSH). Historically, the molecule originated from research on Melanotan II conducted at the University of Arizona. Unlike its predecessor, PT-141 is modified by the removal of the C-terminal amide group. This structural alteration is crucial, as scientists observed that it shifts the pharmacological profile of the molecule—reducing its affinity for receptors responsible for melanogenesis (pigment formation) and concentrating its action primarily on neuroendocrine pathways.
In molecular biology, PT-141 is classified as a non-selective agonist of melanocortin receptors, exhibiting the highest affinity for the MC3R and MC4R subtypes. These receptors are expressed in various regions of the central nervous system, including the hypothalamus and the limbic system. The activation of MC4R in the paraventricular nucleus of the hypothalamus has been identified in the literature as the primary mechanism through which the molecule modulates neuroendocrine signals associated with arousal and sexual behavior in animal models and human subjects.
Scientific interest in PT-141 stems from its unique mechanism of action. While conventional pharmacological agents for sexual dysfunction (such as PDE5 inhibitors) act peripherally by modulating vascular tone and blood flow, studies show that bremelanotide acts centrally. According to published data, the molecule initiates a cascade of neurotransmitter releases in the brain, primarily dopamine in the medial preoptic area (mPOA).
In one of the key early studies published by Diamond et al. (2004), researchers analyzed the effect of PT-141 in male subjects without erectile dysfunction, as well as in those with mild to moderate forms. The data from these Phase II trials demonstrated a statistically significant difference in erectile activity compared to the placebo group, confirming the hypothesis of a centrally mediated response via the melanocortin system [1].
However, the most extensive clinical data comes from studies in women with Hypoactive Sexual Desire Disorder (HSDD). In the Phase III clinical trials known as RECONNECT (Clayton et al., 2019), scientists evaluated the efficacy and safety of bremelanotide in premenopausal women. Subjects in the study receiving subcutaneous injections of the molecule showed a statistically significant increase in the sexual desire index (FSFI-desire) and a reduction in related distress (FSDS-DAO) compared to the placebo group [2]. These results provide robust evidence for the role of MC4R agonists in the neurobiology of sexual behavior.
Understanding the regulatory landscape is a critical part of any objective PT-141 information. In June 2019, the US Food and Drug Administration (FDA) officially approved bremelanotide under the brand name Vyleesi® for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. The molecule also holds approval status from the European Medicines Agency (EMA) for specific indications.
It is important to note that in Bulgaria, bremelanotide (Vyleesi®) is not registered as a medicinal product and is not distributed in pharmacies. In the context of laboratory research, PT-141 is synthesized and offered as a research-grade peptide (raw material for research purposes). Research-grade molecules are intended exclusively for in vitro assays, cell cultures, and validated animal models in a controlled laboratory environment, and are not equivalent to approved medicinal products intended for human use.
Despite the extensive literature, there are several key limitations and questions that the scientific community continues to explore. One of the main challenges observed in clinical trials is the tolerability profile. In the studies by Kingsberg et al. (2019), nausea was reported as the most common adverse event, affecting a significant percentage of subjects (up to 40% in some cohorts), with the incidence being highest at the first administration [3].
Furthermore, scientists continue to study the long-term effects on the cardiovascular system. In some clinical models, a transient increase in systolic and diastolic blood pressure, as well as a decrease in heart rate immediately following administration, has been observed. The mechanism behind these hemodynamic changes is linked to the activation of melanocortin receptors in the autonomic nervous system, but precise mapping of these pathways requires further investigation.
The dynamics of receptor downregulation upon prolonged exposure to MC4R agonists also remain unknown. Researchers are still seeking to answer whether chronic activation of the melanocortin system leads to receptor desensitization and how this might affect the long-term efficacy of the molecule.
Q: What is the difference between PT-141 and Melanotan II? A: PT-141 is a metabolite and structural analogue of Melanotan II. The main difference is the removal of the C-terminal amide group in PT-141. In scientific models, this modification leads to a significant reduction in the melanogenic effect (skin darkening) and a higher selectivity for the neuroendocrine effects associated with MC4R receptors.
Q: How does PT-141 differ from PDE5 inhibitors in clinical models? A: PDE5 inhibitors act at a peripheral level by blocking the enzyme phosphodiesterase type 5 and facilitating vasodilation in specific tissues. Research shows that PT-141 acts centrally in the brain (hypothalamus), activating melanocortin pathways that modulate the neurological signals for arousal themselves.
Q: Why do researchers study the molecule primarily in premenopausal women? A: Although early studies examined the effects in men as well, Phase III clinical data (RECONNECT) demonstrated the clearest statistical efficacy profile against HSDD in premenopausal women. This directed the regulatory and research focus toward this specific demographic group.
[1] Diamond, L. E., Earle, D. C., Heiman, J. R., Rosen, R. C., Perelman, M. A., & Harning, R. (2004). An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. Journal of Sexual Medicine, 1(3), 254-264. [2] Clayton, A. H., Althof, S. E., Kingsberg, S., DeRogatis, L. R., Kaminetsky, J., & Spana, C. (2019). Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Women's Health, 12(3), 325-337. [3] Kingsberg, S. A., Clayton, A. H., Portman, D., Williams, L. A., Krop, J., & Jordan, R. (2019). Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstetrics & Gynecology, 134(5), 899-908.
Disclaimer: This material is strictly educational and informational in nature, representing a review of published scientific literature. The information does not constitute medical advice, diagnosis, or a recommendation for therapy. Research-grade peptides are intended solely for laboratory research and are not suitable for human consumption. For any medical questions or conditions, always consult a qualified physician.
Research reagents for laboratory use. Not medications; not approved for human use.
No comments yet. Be the first.
Comments are reviewed before publishing.
